TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3293408
Drug: Nondrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondrug therapy (blood pressure responders)
Study: 3293408
Drug: Hygienic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygienic therapy
Study: 25423327
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide 800 mg daily
Study: 25423327
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide 1200 mg daily
Study: 18663663
Drug: Serological biomarkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological biomarkers (pepsinogen I, pepsinogen II, gastrin-17, Helicobacter pylori antibodies)
Study: 12658930
Drug: Trimetazidine plus
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine plus routine therapy
Study: 12443576
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy only
Study: 2346354
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of rifamycin SV
Study: 2346354
Drug: Iodinated polyvidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodinated polyvidone dermal solution
Study: 400108
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol (100 microgram four times daily)
Study: 20618675
Drug: Chair‐type training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chair‐type training machine for the elderly, 60‐min sessions twice a week for 12 weeks
Study: 18363672
Drug: Weight-based ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.5 microg/kg/week
Study: 18363672
Drug: Weight-based ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.0 microg/kg/week
Study: 18363672
Drug: PEG-IFN alfa-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Study: 12451365
Drug: Alefacept 7.5
Normalized name: ALEFACEPT 7.5MG/VI INJ KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 7.5 mg
Study: 7547094
Drug: tenidap 120
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenidap 120 mg day-1
Study: 7195230
Drug: AR-L 115
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-L 115 BS, 0.7 mg/kg
Study: 7195230
Drug: Dobutamine, 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine, 0.01 mg/kg
Study: 30921340
Drug: DNA prime
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA prime (ADVAX) and Modified Vaccine Ankara (MVA) boost
Study: 28660370
Drug: Coverage restrictions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coverage restrictions in prescription drug plans
Study: 28660370
Drug: Formulary generosity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulary generosity in prescription drug plans
Study: 25063041
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 2.7 g per day for 2 weeks
Study: 21849055
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care in combination with the particular tape technique
Study: 18611341
Drug: 1,208 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,208 mmol/L (9%) KCl infusion
Study: 18611341
Drug: 201 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 201 mmol/L (1.5%) potassium chloride infusion
Study: 7652501
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g 8-hourly)
Study: 7652501
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g 8-hourly)
Study: 1978026
Drug: IgG3 monoclonal
Normalized name: Anti-Gd2 igg3 monoclonal antibody 3F8 humanized
DrugBank: Naxitamab (DB15965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IgG3 monoclonal antibody
Study: 1978026
Drug: IgG1 monoclonal
Normalized name: Human anti-CD94 IgG1 monoclonal antibody (non-fucosylated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG1 monoclonal antibody
Study: 31682266
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral CBD
Study: 31682266
Drug: Vaporized CBD-dominant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized CBD-dominant cannabis (100 mg CBD; 3.7 mg ∆9-THC)
Study: 17201801
Drug: Replacement-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement-dose recombinant methionyl human leptin (r-metHuLeptin) during 72-hour fasting
Study: 17201801
Drug: 72-hour fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72-hour fasting (without leptin administration)
Study: 11880017
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg
Study: 11226112
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 mL
Study: 3276279
Drug: Methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500 mg/d)
Study: 3276279
Drug: Oxprenolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (80 mg/d)
Study: 18482454
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg elemental iron (as ferrous fumarate) multivitamin
Study: 18482454
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron (as ferrous sulphate) multivitamin
Study: 16169655
Drug: Dentin-bonding agent
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentin-bonding agent
Study: 11113718
Drug: Atenolol (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (maintenance dose 89±11 mg/day, range 50-100 mg/day)
Study: 8474401
Drug: Amitriptyline oxide
Normalized name: amitriptyline oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline oxide (60 mg)
Study: 6743780
Drug: Trimipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (50 mg)
Study: 3776446
Drug: Intramuscular oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxycodone on request following an intraoperative intercostal block (Group C)
Study: 3776446
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine as a continuous infusion of 0.25% bupivacaine (Group EB)
Study: 3776446
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4 mg injected prior to surgery and on the first postoperative morning (Group EM4)
Study: 3776446
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 6 mg injected prior to surgery and on the first postoperative morning (Group EM6)
Study: 29529169
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + AAP (abiraterone acetate 1000 mg + prednisolone 5 mg daily)
Study: 29529169
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + DocP (docetaxel 75 mg/m2 3-weekly x 6 + prednisolone 10 mg daily)
Study: 19875232
Drug: Pain Clinic
Normalized name: Stopain Clinical
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Clinic treatment
Study: 18160741
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone antagonist plus testosterone administration for 4 weeks
Study: 16177164
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide treatment (NO); N2O and EMLA
Study: 16177164
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CO); cutaneous application of EMLA
Study: 16177164
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide treatment (NO)
Study: 16177164
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide treatment (NO) and Conventional treatment (CO)
Study: 12709682
Drug: Diltiazem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (1 g/kg/min during CPB)
Study: 11128561
Drug: Teicoplanin 400
Normalized name: Teicoplanin 400 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 400 mg/day i.m. for a minimum of 4 months
Study: 11128561
Drug: Teicoplanin 200
Normalized name: Teicoplanin 200 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 200 mg/day i.m. (reduced dose for 2 patients)
Study: 11128561
Drug: Teicoplanin treatment
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin treatment
Study: 6388897
Drug: Neomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (2 g/day)
Study: 6388897
Drug: Neomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin plus Niacin (3 g/day)
Study: 6388897
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Neomycin plus Niacin
Study: 6388897
Drug: Diet-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-only therapy
Study: 31402718
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (NAPSO) 440 mg
Study: 26573022
Drug: Ceftobiprole 500
Normalized name: ceftobiprole medocaril sodium 667 MG (equivalent to ceftobiprole 500 MG) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftobiprole 500 mg, administered by 2-hour intravenous infusion every 8 hours.
Study: 27129122
Drug: PRTX-100 (0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRTX-100 (0.15, 0.45, 0.90, or 1.50 µg/kg)
Study: 22959335
Drug: Reduced-intensity conditioning
Normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity conditioning (4 doses of 2 Gy total-body irradiation and 150 mg/m² fludarabine)
Study: 22959335
Drug: Standard conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conditioning (6 doses of 2 Gy total-body irradiation and 120 mg/kg cyclophosphamide)
Study: 18156036
Drug: COX-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2 inhibitors (rofecoxib, celecoxib, sulindac, meloxicam, indometacin) with low-dose aspirin
Study: 18156036
Drug: COX-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2 inhibitors with low-dose aspirin
Study: 18156036
Drug: COX-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2 inhibitors (celecoxib, rofecoxib) with low-dose aspirin
Study: 18156036
Drug: Non-selective NSAIDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective NSAIDs with low-dose aspirin
Study: 15074088
Drug: Imitate preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitate preparation in control group
Study: 16098301
Drug: Dobutamine stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine stress echocardiography with real-time low mechanical index perfusion imaging (using intravenous Optison)
Study: 8743516
Drug: Ca antagonists
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca antagonists
Study: 1656826
Drug: Intravenous foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous foscarnet at a dose of 60 mg/kg body weight three times a day for 3 weeks followed by 90 mg/kg once a day (treatment group)
Study: 1656826
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (delayed treatment, control group)
Study: 1656826
Drug: Intravenous foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous foscarnet treatment
Study: 1656826
Drug: Foscarnet treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet treatment
Study: 30951586
Drug: Home-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based behavioral skills treatment
Study: 20810101
Drug: Maintenance antidepressants
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressants (mADM)
Study: 15757007
Drug: Inpatient relapse
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient relapse prevention (RP) program (treatment goal met)
Study: 15757007
Drug: Inpatient relapse
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient relapse prevention (RP) program (treatment goal not met)
Study: 7541435
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g every 6 hr)
Study: 31299655
Drug: Tiopronin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin (3 g daily for up to 14 days after aSAH)
Study: 25904586
Drug: Particle-filtered air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particle-filtered air (PM2.5 levels of 3 µg/m(3))
Study: 25904586
Drug: Sham-filtered air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-filtered air (PM2.5 levels of 24 µg/m(3))
Study: 12027853
Drug: Bicarbonate infusion
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate infusion
Study: 23552179
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (in subset with baseline creatinine clearance < 60 mL/min)
Study: 23552179
Drug: Bicarbonate infusion
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate infusion (in subset with baseline creatinine clearance < 60 mL/min)
Study: 17265545
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi training (18 weeks, 45 min, twice a week)
Study: 16100235
Drug: GIK (glucose-insulin-potassium)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (glucose-insulin-potassium) treatment
Study: 16100235
Drug: GIK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK treatment
Study: 10521999
Drug: 3-day intravenous
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus ampicillin/salbactum (1.5 gm i.v. loading then 750 mg q 9 am, 3 pm, & 9 pm)
Study: 10521999
Drug: 3-day intravenous
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus metronidazole and erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Study: 10521999
Drug: 3-day intravenous
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Study: 10521999
Drug: Oral dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dual therapy (omeprazole 20 mg and amoxycillin 1 g bid x 2 weeks)
Study: 10521999
Drug: 3-day intravenous
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day intravenous regimens (Groups 1-3)
Study: 7491890
Drug: 130 g
Normalized name: ISOPROPYL ALCOHOL 1130 g in 400 TOPICAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 g dry lentils/d
Study: 1791775
Drug: Control (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (50 mg oestradiol implant)
Study: 6754212
Drug: Levonantradol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonantradol 0.5 mg
Study: 6754212
Drug: Levonantradol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonantradol 0.75 mg
Study: 6754212
Drug: Chlorpromazine 26
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine 26 mg
Study: 19732445
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving 500 mg medicinal starch daily
Study: 19732445
Drug: GTP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTP group receiving 500 mg of GTP per day
Study: 19732445
Drug: Placebo+TC group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+TC group receiving both placebo treatment and TC training (60‐minute group exercise, 3 times per week)
Study: 10667742
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of risperidone or haloperidol (maximum, < or = 6 mg/day)
Study: 25663
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg alone
Study: 25663
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg alone
Study: 25663
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Study: 25663
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Study: 30106348
Drug: 24-hour metformin
Normalized name: metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 24-hour metformin discontinuation
Study: 30106348
Drug: 48-hour metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-hour metformin discontinuation
Study: 30106348
Drug: No metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No metformin discontinuation (control)
Study: 26577455
Drug: 0.1 mm
Normalized name: gadobenate dimeglumine 529 mg/mL (0.1 mmol/0.2 mL) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mm MAL cream
Study: 26577455
Drug: 0.2 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mm MAL cream
Study: 26577455
Drug: 0.4 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mm MAL cream
Study: 26577455
Drug: 1.0 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mm MAL cream
Study: 22397710
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional modality treatments only)
Study: 12370681
Drug: Remifentanil infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion, BIS-titrated
Study: 7478084
Drug: GnRH Analogues
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH Analogues therapy
Study: 7478084
Drug: GnRH Analogues
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH Analogues therapy with Ipriflavone
Study: 6112998
Drug: Gallamine 10
Normalized name: gallamine
DrugBank: Gallamine (DB13584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallamine 10 mg
Study: 6112998
Drug: Gallamine 20
Normalized name: gallamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine 20 mg
Study: 6112998
Drug: Tubocurarine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine 5 mg
Study: 6112998
Drug: Pancuronium 1
Normalized name: pancuronium 1 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 1 mg
Study: 31999335
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic prophylaxis (SAP) for 2 to 14 days after admission
Study: 31999335
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic prophylaxis (SAP)
Study: 31786720
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on ≥ 4 drugs
Study: 31786720
Drug: Patients at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients at risk of serious or very serious drug interactions
Study: 31786720
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between number of drugs taken and risk of serious or very serious interaction
Study: 27258567
Drug: Novel triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel triple IHC antibody cocktail (TNP) composed of TTF1, Napsin A, and p40.
Study: 27699179
Drug: Medtable™ medication-planning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtable™ medication-planning tool
Study: 25027101
Drug: OMEGA‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMEGA‐3 polyunsaturated fatty acids (200 mg/kg/day starting before anesthesia induction for 24 hours followed by 100 mg/kg/day for 7 days)
Study: 18936475
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN) monotherapy
Study: 8644655
Drug: c7E3 bolus
Normalized name: c7E3
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 bolus and infusion
Study: 6391391
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution without bicarbonate
Study: 6391391
Drug: World Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: World Health Organisation oral rehydration solution (control)
Study: 22300423
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice daily)
Study: 29112461
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Vitamin D supplementation (1250 mg calcium carbonate and 400 IU vitamin D3)